Evolution of delayed resistance to immunotherapy in a melanoma responderDavid Liu, Genevieve M. Boland, Jia‐Ren Lin et al.|Nature Medicine|2021Cited by 135
Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast CancerAdam Kraya, Katherine L. Nathanson, Amanda Barrett et al.|Clinical Cancer Research|2019Cited by 103
Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific driversJennifer Shah, Katherine L. Nathanson, Dana Pueschl et al.|Nature Communications|2022Cited by 27
HGG-32. PNOC008: A PILOT TRIAL TESTING THE CLINICAL BENEFIT OF USING MOLECULAR PROFILING TO DETERMINE AN INDIVIDUALIZED TREATMENT PLAN IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED HIGH-GRADE GLIOMA (EXCLUDING DIFFUSE INTRINSIC PONTINE GLIOMA)Andrea Franson, Sabine Mueller, Lindsay Kilburn et al.|Neuro-Oncology|2024Cited by 2